Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Drug Resistant Epilepsy in the MORE Multicenter Patient Registry.

, health-related quality of life (Quality of Life in Epilepsy Inventory 31, QOLIE-31), depression, and safety outcomes.ResultsOf the 191 patients recruited 170 (mean (SD) age of 35.6 (10.7) years, 43% female) were implanted with DBS Therapy and met all eligibility criteria. At baseline, 38% of patients reported cognitive impairment. The median monthly SF decreased by 33.1% from 15.8 at baseline to 8.8 at 2 years (P<0.0001) with 32.3% RR. In the subgroup of 47 patients that completed 5 years of follow-up, the median monthly SF decreased by 55.1% from 16 at baseline to 7.9 at 5 years (P<0.0001) with 53.2% RR. Factors influencing SF reduction included number of implants per center. In patients with cognitive impairment, the reduction in median monthly seizure frequency was 26.0% by two years compared with 36.1% in patients without cognitive impairment. The most frequently reported adverse events were changes (e.g. increased frequency/severity) in seizure (16%), memory impairment (patient reported complaint, 15%), depressive mood (patient reported complaint, 13%) and epilepsy (12%). One definite Sudden Death in Epilepsy (SUDEP) case was reported.DiscussionThe MORE registry supports the effectiveness and safety of ANT-DBS therapy in a real-world setting in the 2-years following implantation.